Video

Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.

Transcript

What challenges are associated with conducting precision medicine trials in the community setting?

So, with precision medicine, you need to have tissue, and if you need new tissue, that is sometimes a barrier based on location or cost and toxicity of getting the new tissue. There is a barrier of getting the testing done, whether that’s on a research study or before the research program actually and the eligibility criteria, which may limit patient accrual. For many of these patients that have been through multiple lines of therapy and there aren’t a lot of great options, anything that slows things down can cause them to go from relatively healthy and able to go on a trial, to unhealthy and unable to go on the trial, or even dying. So, this has been seen, and we have to do things efficiently and fast in order to overcome these accrual barriers.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Screenshot of Susan Wescott, RPh, MBA
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with Adam Colborn, JD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo